New antibody therapy shows promise for cancer treatment

Researchers at King’s College London have developed a new IgE antibody therapy that activates the immune system to target HER2-positive breast and ovarian cancers. This approach could help patients who do not respond to current treatments. The IgE therapy works differently from the common IgG antibodies, activating immune cells in a unique way. In tests on mice with resistant tumors, the IgE therapy successfully directed immune responses against cancer cells and slowed tumor growth. Next steps include developing the therapy for human use, with potential availability in 3 to 5 years. This breakthrough could provide a new treatment option for patients with aggressive cancers that are hard to treat.